Disclaimer The information contained in this confidential document ("Presentation") has been prepared by CHC Healthcare Group (the "Company"). It has not been fully verified

and is subject to material updating, revision and further amendment.

While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or

advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or

completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any

interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the

Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or

indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions

contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any

transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be

responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company

does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any

inaccuracies in, or omissions from, this Presentation which may become apparent.

This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or

advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and

taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of

subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

This Presentation includes certain statements that may be deemed “forward-looking statements”. All statements in this discussion, other than statements of

historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company

believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future

performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ

materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business

conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially

from those projected in forward-looking statements.

1

Swissray Global Healthcare Holding Ltd. (4198)

Institutional Investor Conference

Gilbert Wai, CEO

2016 Dec. 15th

Swissray Medical AG Mfg/Sales&Service

Swissray International Inc. R&D/Mfg/Sales&Service

Swissray Asia Healthcare Co. Ltd.

Sales&Service

Swissray Global Healthcare Holding Ltd.

(4198) Headquarter

SMTH AG Holding Co.

Founded in 2013 Listed on Dec. 23, 2014

Founded in 2009

Founded in 1988 Founded in 2002 Founded in 2011

100%

100% 100% 100%

New Jersey, USA Wisconsin, USA Taipei, Taiwan Hochdorf, Switzerland 3

Company Organizational Structure

Founded in 2015

Swissray Healthcare Holding (H.K.) Ltd.

Global Network Channels

4

China Taiwan Hong Kong Thailand Australia New Zealand

USA Brazil Costa Rica Jamaica Columbia

Switzerland Germany Austria France Netherlands Belgium

1 4

3 5

2

7

9

8

6

Russia Romania Czech Iran UAE Egypt

EMEA

APAC Americas

Philippines Vietnam Singapore Indonesia Malaysia Myanmar

Europe, Middle East, Africa Asia, Oceania, Greater China North America, South America

Current Product Line (1/5)

5

Surgical Products

Novadaq

Bone Health Products

Norland

X-ray Products

Swissray

6

Current Product Line (2/5)

ddRAura – released to the market in 2016

7

Set up demo site at Tower Radiology & Breast Center in October 2016

• Smarter Technology for Smoother Workflow • A Comprehensive System for More Versatility • Total System Automation for Ultimate

Workflow Efficiency • Different Configurations for Different

Requirements • Advance and Affordable Workflow Redefined • A User Interface with a Difference • Single Focus Stitching for Higher Accuracy

Current Product Line (3/5)

ddRAura™OTC

ddRAura™OTC APS

ddRAura™FMTS

Norland: Bone densitometer

8

Norland Elite Target to the bariatric and athletic

markets

Norland XR-800

Norland XR-600

Current Product Line (4/5)

Novadaq: Real Time Fluorescence Image System

9

Current Product Line (5/5)

First SPY Case in Kuala Lumpur Hospital in Malaysia PinPoint well received at Rajavithi Hospital in Thailand

Distributor in Vietnam: Schmidt Biomedtech Japanese scholar promoting in International Conference

10

SR Pulse 710 1.5T Wide-Bore Magnetic Resonance Imaging

MRI Market Analysis (1/4)

11

2016 VS 2021

Source: MarketsandMarkets, 2016

Global MRI market reached to US$ 5.6 billion in 2016 Expected to be approximately US$ 7.2 billion by 2021

Compound annual growth rate of 5.1%

12 Source: MarketsandMarkets, 2016

SHARE OF THE MRI SYSTEMS MARKET IN 2021

1.5T High-field MRI accounts for more than 45% of total MRI market

MRI Market Analysis (2/4)

MRI Market Analysis (3/4)

13

GEOGRAPHICAL SNAPSHOT: 2015

Source: MarketsandMarkets, 2016

North America market accounts for 31.4% of the global market- the largest market for MRI

MRI Market Analysis (4/4)

14

“The closed MRI systems segment is the fastest-growing segment of the MRI systems market. The high growth rate of this segment is attributed to the ongoing focus on replacement of narrow-bore (60 cm) closed MRI scanners with wide-bore (70 cm) closed MRI scanners. “

Source: MarketsandMarkets, 2016

SR Pulse 710 Magnetic Resonance Imaging

15

1.5T, 710 mm Wide-Bore High

Performance

State-of-the-Art Features

Cryogen Zero Boil-off

Made in USA

Market price of similar products US$ 1.1-1.5 million

16

SR Pulse 710 Total Cost of Ownership

Fastest Break Even Potential

Fastest ROI

* MD buyline comparison of 1.5T Wide-Bore systems 8/2015- 8/2016

Swissray SR Pulse 710 Swissray SR Pulse 710

Radiological Society of North America (1/5)

17

RSNA Theme: BEYOND IMAGING Swissray’s Theme: BEYOND DR

November 27 - December 2, 2016 @ Chicago

Radiological Society of North America (2/5)

18

19

Radiological Society of North America (3/5)

Radiological Society of North America (4/5)

20

Radiological Society of North America (5/5)

21

22

SR Pulse 710 - Publication in Diagnostic Imaging Europe

ddRAura - Publication in Diagnostic Imaging Europe

23

24

Ionizing Radiation X-ray / Norland DXA

Imaging Diagnostic MRI/ Ultrasound/ CT

Radiation Therapy

Hig

he

r V

alu

e

Product Expansion Strategy

SR Pulse 710

Beyond DR ddR series Future

Digital X-ray

ddRFormula ddRElement ddRVersa ddRCruze ddRAura FMTS ddRAura OTC ddRImpulse …

Diagnosis Imaging

MRI Ultrasound CT PET/CT … DXA (2013) Novadaq (2013)

Radiation Therapy

Radiotherapy System

2016 2017-2018 2019-2020

Thank you for your time.

25